10.34
-0.58%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Moberg Pharma AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker MOB.ST. It has been listed since 26 May 2011. In the fiscal year to 31 December 2025, it reported revenue of SEK 13.5m and a net loss of SEK 27.2m. At that date it held total assets of SEK 682.3m and shareholders' equity of SEK 665.2m.
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 May 2011
- Employees
- 12
- Website
- mobergpharma.se ↗
Leadership
Pay as last reported
- Dr. Jonas EkblomIndependent Chairman of the Board
- Ms. Anna LjungChief Executive Officer, since 2019SEK 325,000
- Mr. Mark BeveridgeVice President - Finance, since 2019
- Ms. Christina ErixonSenior Director Product Management
- Ms. Annica MagnussonSenior Director Regulatory Affairs
- Mr. Richard DingIndependent Director
- Ms. Isabelle DucellierIndependent Director
- Mr. Otto SkollingIndependent Director
- Mr. Nikolaj SorensenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Moberg Pharma AB develops products for skin diseases and pain treatment including Emtrix/Nalox and Kerasal.
- The company has two phase II development projects, MOB-15 for nail fungus and Limtop for skin conditions.
- Moberg Pharma AB collaborates with Meda AB, Menarini Group, and Perrigo Company for product commercialization.
Weaknesses
- Moberg Pharma AB employs only 12 full-time employees, limiting operational capacity.
- The company's product portfolio is limited to skin and pain treatments with no diversification.
- Moberg Pharma AB operates in over 35 countries but lacks a strong presence in major markets.
Opportunities
- Moberg Pharma AB can expand its OTC brands in the United States market.
- The company's phase II projects MOB-15 and Limtop offer potential for new revenue streams.
- Moberg Pharma AB can leverage collaborations with Meda AB and Menarini Group for global market access.
Threats
- Moberg Pharma AB faces competition from established pharmaceutical companies in skin treatment markets.
- The company's small employee count may hinder rapid response to market changes.
- Moberg Pharma AB's reliance on a narrow product portfolio increases vulnerability to market shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.